CRISPR Therapeutics AG (NASDAQ:CRSP) on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its gene-editing and RNA-based pipeline.
Casgevy Uptake
Casgevy, the company’s gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in fourth-quarter revenue and $116 million for the full year.
A total of 64 patients received infusions in 2025, including 30 during the fourth quarter.
Globally, 147 patients initiated treatment through the first cell collection during the year. Patient initiations nearly tripled compared to 2024, reflecting growing momentum heading into 2026.
William Blair noted, “the increase to 147 first cell collections strengthens confidence that higher initiation volumes will translate into materially greater revenue in 2026.”
Access to Casgevy continued to expand across key markets, with reimbursement now covering roughly 90% of eligible patients in the U.S. The therapy is also reimbursed across several European and Middle Eastern markets. In January, partner Vertex Pharmaceuticals Inc. (NASDAQ: